GlassScriptPhysician profile
Elham Mohammadirad
NPI 1619491073
$4,369.97
in general payments reported to CMS, 2019-2025
27 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $262 · 2021: $537 · 2022: $399 · 2023: $833 · 2024: $891 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,042.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.84 | 2021-2025 | |
| Novo Nordisk INC | $643.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $550.31 | 2021-2025 | |
| Lilly USA, LLC | $395.05 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.29 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $269.99 | 2021-2022 | |
| Glaxosmithkline, LLC. | $193.09 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Idorsia Pharmaceuticals US INC | $146.17 | 2023-2025 | Quviviq, Quviviq |
| Genentech USA, INC. | $128.29 | 2019 | |
| Exact Sciences Corporation | $116.31 | 2024-2025 | Cologuard Collection Kit |
| Indivior INC. | $116.04 | 2021-2022 | |
| Gilead Sciences, INC. | $115.90 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $104.81 | 2022-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $97.30 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Sumitomo Pharma America, INC. | $93.82 | 2023-2025 | Gemtesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $92.70 | 2023-2025 | Gardasil 9, M-M-R II, Capvaxive |
| Phathom Pharmaceuticals, INC. | $83.72 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $46.50 | 2021 | |
| Verona Pharma, INC. | $41.02 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $26.79 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $24.64 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $20.72 | 2021 | |
| Amgen INC. | $19.65 | 2024 | Repatha, Otezla |
| Daiichi Sankyo INC. | $18.81 | 2020 | |
| Ardelyx, INC. | $15.90 | 2023 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $15.70 | 2022 | |
| Shield Therapeutics INC | $13.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elham Mohammadirad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.